pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
YESAFILI · news · pharmadog
← back to YESAFILI
News mentioning YESAFILI
13
stories
1d
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
4d
EyePoint’s bid to compete with Eylea falls flat
endpoints
4d
EyePoint plummets on pivotal data for main drug
biopharma dive
4d
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
biospace
10d
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
biospace
11d
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
22d
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
25d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
29d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
May 6, 26
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
biopharma dive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
